{
  "success": true,
  "pagesUsed": [
    6,
    9,
    41,
    42,
    46,
    47,
    48,
    53,
    54,
    56,
    57
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Paclitaxel Cycle Start Interval",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Previous Visit",
        "windowLower": -3,
        "windowUpper": 3
      },
      {
        "id": "timing_2",
        "name": "FOLFIRI Cycle Start Interval",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Previous Visit",
        "windowLower": -3,
        "windowUpper": 3
      },
      {
        "id": "timing_3",
        "name": "Erlotinib Cycle Start Interval",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "Previous Visit",
        "windowLower": -3,
        "windowUpper": 3
      },
      {
        "id": "timing_4",
        "name": "Docetaxel Cycle Start Interval",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "Previous Visit",
        "windowLower": -3,
        "windowUpper": 3
      },
      {
        "id": "timing_5",
        "name": "Paclitaxel Cycle Duration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_6",
        "name": "FOLFIRI Cycle Duration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "Erlotinib Cycle Duration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_8",
        "name": "Docetaxel Cycle Duration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_9",
        "name": "Paclitaxel Administration Days",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_10",
        "name": "NSAID Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_11",
        "name": "Investigational Product Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_12",
        "name": "GI Perforation/Fistula History Exclusion",
        "type": "Before",
        "unit": "months",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_13",
        "name": "Wound/Ulcer/Bone Fracture Exclusion",
        "type": "Before",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_14",
        "name": "Major Surgery Exclusion",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_15",
        "name": "Central Venous Access Device Placement",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_16",
        "name": "Hemoptysis History Exclusion (NSCLC)",
        "type": "Before",
        "unit": "months",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_17",
        "name": "CNS Metastases Stability Requirement",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_18",
        "name": "Rescreening Interval",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Screening",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_19",
        "name": "Maximum Treatment Delay",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 28
      },
      {
        "id": "timing_20",
        "name": "Loading Dose Re-administration Threshold",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_21",
        "name": "Withhold Ramucirumab Before Surgery",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_22",
        "name": "Proteinuria Dose Delay",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 14
      },
      {
        "id": "timing_23",
        "name": "Grade 3 AE Resolution Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 28
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Cycle 1 Dosing Criteria - Bilirubin",
        "instanceType": "Condition",
        "description": "Hepatic function requirement for weekly dosing in Cycle 1",
        "text": "Total bilirubin ≤1.5x upper limit of normal (ULN) or baseline (whichever is greater)"
      },
      {
        "id": "cond_2",
        "name": "Cycle 1 Dosing Criteria - ALT/AST Low Baseline",
        "instanceType": "Condition",
        "description": "Hepatic function requirement for weekly dosing in Cycle 1 when baseline is low",
        "text": "ALT and AST ≤3x ULN, if baseline <1.5x ULN"
      },
      {
        "id": "cond_3",
        "name": "Cycle 1 Dosing Criteria - ALT/AST High Baseline",
        "instanceType": "Condition",
        "description": "Hepatic function requirement for weekly dosing in Cycle 1 when baseline is elevated",
        "text": "ALT and AST ≤2x baseline, if baseline ≥1.5x ULN"
      },
      {
        "id": "cond_4",
        "name": "New Cycle Dosing Criteria - ANC",
        "instanceType": "Condition",
        "description": "Hematologic requirement for new cycle",
        "text": "Absolute neutrophil count (ANC) ≥1.5x 10^3/μL (≥1.5x 10^9/L)"
      },
      {
        "id": "cond_5",
        "name": "New Cycle Dosing Criteria - Platelets",
        "instanceType": "Condition",
        "description": "Hematologic requirement for new cycle",
        "text": "Platelets ≥100x 10^3/μL (≥100x 10^9/L)"
      },
      {
        "id": "cond_6",
        "name": "New Cycle Dosing Criteria - AE Resolution",
        "instanceType": "Condition",
        "description": "Adverse event resolution requirement for new cycle",
        "text": "Ramucirumab-related AEs that are NCI CTCAE v5.0 Grade <2 or equivalent severity to baseline (except for alopecia; for hypertension and proteinuria, see Section 6.5.1.8)"
      },
      {
        "id": "cond_7",
        "name": "HIV Positive Eligibility",
        "instanceType": "Condition",
        "description": "Conditions for HIV positive participants to be eligible",
        "text": "HIV positive participants excluded unless well controlled on HAART with no AIDS-defining opportunistic infections within last 2 years and CD4 count >350 cells/μL"
      },
      {
        "id": "cond_8",
        "name": "Proteinuria UPCR Threshold",
        "instanceType": "Condition",
        "description": "Proteinuria threshold for dose modification",
        "text": "UPCR ≥2 (or ≥200 mg/mmol) requires dose modification"
      },
      {
        "id": "cond_9",
        "name": "Hypertension Control Requirement",
        "instanceType": "Condition",
        "description": "Hypertension must be controlled before resuming treatment",
        "text": "Hypertension controlled with medication and resolved to Grades 0-2"
      },
      {
        "id": "cond_10",
        "name": "Grade 3 AE Resolution Criteria",
        "instanceType": "Condition",
        "description": "Criteria for resuming treatment after Grade 3 AE",
        "text": "Non-life-threatening and reversible Grade 3 clinical AEs that resolve to Grade ≤1 or pretreatment baseline within 21 to 28 days"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Discontinuation for Grade 4 AE",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If a Grade 4 AE occurs and is deemed at least possibly related to ramucirumab, then ramucirumab should be discontinued except in the specific case of Grade 4 fever or Grade 4 laboratory abnormalities"
      },
      {
        "id": "trans_2",
        "name": "Discontinuation for Treatment Delay >4 Weeks",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If a delay of greater than 4 weekly doses is necessary due to ramucirumab-related, unresolved toxicity, ramucirumab SC should be discontinued"
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Hypersensitivity Grade 3-4",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for Grade 3-4 hypersensitivity reaction"
      },
      {
        "id": "trans_4",
        "name": "Discontinuation for Uncontrolled Hypertension",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for uncontrolled hypertension, hypertensive crisis, or hypertensive encephalopathy (Grade 4)"
      },
      {
        "id": "trans_5",
        "name": "Discontinuation for Arterial/Venous Thromboembolic Events",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for Grade 3 or 4 arterial or venous thromboembolic events"
      },
      {
        "id": "trans_6",
        "name": "Discontinuation for Bleeding/Hemorrhage Grade 3-4",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for Grade 3 or 4 bleeding/hemorrhage"
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for GI Perforation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for gastrointestinal perforation"
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for PRES",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for posterior reversible encephalopathy syndrome"
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for CHF Grade 3-4",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for Grade 3 or 4 congestive heart failure"
      },
      {
        "id": "trans_10",
        "name": "Discontinuation for Fistula Formation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Immediately and permanently discontinue ramucirumab for fistula formation"
      },
      {
        "id": "trans_11",
        "name": "Discontinuation for Nephrotic Syndrome",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Discontinue study treatment for proteinuria UPCR >3 (or >300 mg/mmol) or in the setting of nephrotic syndrome"
      },
      {
        "id": "trans_12",
        "name": "Discontinuation for Persistent Proteinuria",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If UPCR remains ≥2 (or ≥200 mg/mmol) after 14 days, discontinue study treatment"
      },
      {
        "id": "trans_13",
        "name": "Discontinuation for Second Proteinuria Occurrence",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Second occurrence of UPCR ≥2: Discontinue study treatment"
      },
      {
        "id": "trans_14",
        "name": "Discontinuation for Hepatic Encephalopathy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Ramucirumab should be discontinued in the event of any new occurrence of hepatic encephalopathy and/or hepatorenal syndrome resulting from liver cirrhosis"
      },
      {
        "id": "trans_15",
        "name": "Dose Modification for Grade 3 AE",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Dose modifications are permitted only for ramucirumab maintenance dose in the setting of non-life-threatening and reversible Grade 3 clinical AEs considered to be at least possibly related to ramucirumab that resolve to Grade ≤1 or pretreatment baseline within 21 to 28 days"
      },
      {
        "id": "trans_16",
        "name": "Dose Modification for Proteinuria",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If UPCR ≥2 (or ≥200 mg/mmol), omit ramucirumab dose until UPCR returns to <2. Resume ramucirumab at reduced dose"
      },
      {
        "id": "trans_17",
        "name": "Continuation to Monotherapy",
        "instanceType": "TransitionRule",
        "transitionType": "Arm Transition",
        "text": "If participants have discontinued combination anti-cancer therapy, ramucirumab SC may be continued as monotherapy until progressive disease, at the discretion of the investigator"
      },
      {
        "id": "trans_18",
        "name": "Loading Dose Re-administration",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Re-administration of loading dose is required only if ≥30 days has elapsed since the last ramucirumab SC dose"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Progressive Disease",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Ramucirumab SC may be continued as monotherapy until progressive disease"
      },
      {
        "id": "exit_2",
        "name": "Life-Threatening Event",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Ramucirumab will be permanently discontinued in case of any ramucirumab-related event that is deemed life-threatening, regardless of grade"
      },
      {
        "id": "exit_3",
        "name": "Symptomatic Deterioration",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Any symptomatic deterioration or clinical disease progression requiring other forms of specific antitumor systemic therapy will be cause for discontinuation of study therapy"
      },
      {
        "id": "exit_4",
        "name": "Wound Healing Complications",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "If a participant develops wound-healing complications during therapy, discontinue ramucirumab until the wound is fully healed"
      },
      {
        "id": "exit_5",
        "name": "Inadvertent Enrollment",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Discontinuation of inadvertently enrolled participants"
      },
      {
        "id": "exit_6",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant lost to follow-up"
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Cycle 1 Weekly Dosing Decision",
        "timepointId": "each_weekly_dose_cycle1",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for administering each weekly dose in Cycle 1 based on hepatic function criteria",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3"
        ]
      },
      {
        "id": "dec_2",
        "name": "New Cycle Start Decision",
        "timepointId": "start_new_cycle",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for starting each new cycle based on hepatic, hematologic, and AE resolution criteria",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6"
        ]
      },
      {
        "id": "dec_3",
        "name": "Proteinuria Assessment Decision",
        "timepointId": "proteinuria_check",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for dose modification based on proteinuria UPCR levels",
        "conditionIds": [
          "cond_8"
        ]
      },
      {
        "id": "dec_4",
        "name": "Hypertension Management Decision",
        "timepointId": "hypertension_check",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for resuming treatment after Grade 3 hypertension",
        "conditionIds": [
          "cond_9"
        ]
      },
      {
        "id": "dec_5",
        "name": "Treatment Delay Decision",
        "timepointId": "treatment_delay_assessment",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for continuing or discontinuing treatment based on duration of delay",
        "conditionIds": [
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 23,
      "conditionCount": 10,
      "transitionRuleCount": 18,
      "exitCount": 6
    }
  }
}